President – Lynn DeLisi, M.D.
Lynn E. DeLisi, MD, is currently an Attending Psychiatrist in the VA Boston Healthcare System and Professor of Psychiatry at Harvard Medical School. In addition, she is editor-in-chief and co-founder of the Elsevier journal, Schizophrenia Research. She was secretary, as well as co-founder, of two professional organizations: The Schizophrenia International Research Society (SIRS) and the International Society of Psychiatric Genetics (ISPG). She is also an active fellow of the American College of Neuropsychopharmacology. Her undergraduate degree is in zoology from the the University of Wisconsin, Madison, Wisconsin. She obtained her M.D. degree from the Medical College of Pennsylvania and went on from there to do 3 years of general practice work with the migrant Chile farmers of Northern New Mexico. She completed a residency in psychiatry at Saint Elizabeth’s Hospital, Washington DC, and then went on to complete a post-doctoral fellow and then remain as a full time staff research psychiatrist in the NIMH intramural research program, at both St. Elizabeth’s Hospital and in Bethesda, Maryland. In 1987, she left NIMH to assume a professorship at the State University of New York at Stony Brook where she set up several research programs on the longitudinal biological outcome of schizophrenia, emphasizing both brain imaging and genetic studies. During this time, she was the first to conduct a longitudinal controlled MRI study that showed progressive brain change in schizophrenia and was a pioneer in developing an international collaboration for ascertainment of families with multiple members having schizophrenia to be used in molecular genetic studies. From 2001 through 2008, she was professor at New York University School of Medicine and Associate Director of the brain imaging division at the Nathan Kline Institute for Psychiatric Research where she contributed several studies on anomalies of language processing in people at high risk for schizophrenia. She moved to her current position in the Boston area in January 2009 where she continues to focus her research on biological markers for high risk for schizophrenia.
Til Wykes is Professor of Clinical Psychology and Rehabilitation and Vice Dean for Psychology and Systems Sciences at the Institute of Psychiatry, Psychology and Neuroscience at King’s College London. Her active research stretches across the impact pathway which includes basic understanding of the causes and effects of psychosis, the development and evaluation of novel psychological treatments and testing implementation so they can be rolled out into services. She also has research in digital health and active and passive monitoring. She actively collaborates with consumers in the Service User Research Enterprise (SURE) (founder and co-director) and leads the Patient and Carer Participation theme of the NIHR Biomedical Research Centre in Mental Health. She has been the chair of the SIRS Ethics Committee as well as Secretary and Treasurer of the Society. She is the executive editor of the Journal of Mental Health and serves on the editorial boards of NPJ Schizophrenia, Schizophrenia Research and Schizophrenia Bulletin. She is an elected fellow of the Academy of Medical Sciences, the Academy of Social Sciences and the British Psychological Society. In 2016 her work was recognized through the award of a Damehood by the Queen and in 2017 she achieved a Guinness World Record for the largest mental health lesson.
Past President – Patrick McGorry, FRCP, M.D., Ph.D.
Patrick D. McGorry is Executive Director of Orygen Youth Health, Australia’s largest youth mental health organisation, comprising an internationally recognized translational research centre and a clinical service targeting the needs of young people with emerging serious mental illness. He is also Professor of Youth Mental Health at the University of Melbourne, a Founding Director of the National Youth Mental Health Foundation (headspace), and the current President of the Australasian Society for Psychiatry Research (2013-2015).
Professor McGorry is a world-leading researcher in the area of early psychosis and youth mental health. He began his research career in the mid 1980s with a major focus on schizophrenia, which has continued throughout his career, focused on the early stages of illness. His innovative, ground-breaking research has played an integral role in the development of safe, effective treatment strategies that have helped improve the lives of large numbers of young people and their families.
Orygen Youth Health’s integrated early psychosis service, known as EPPIC, was founded by Professor McGorry in 1992. Within a year EPPIC had included a specialised clinical research clinic PACE for prodromal or ultra high risk patients, and this early psychosis platform has been hugely influential internationally. EPPIC’s evidence-based model has been emulated and evolved in all continents, and early intervention in psychosis has become one of the major growth points in international mental health research and reform. In 1997, Professor McGorry led the establishment, in collaboration with a number of other leading schizophrenia and early psychosis researchers, of the International Early Psychosis Association or IEPA, which has overseen the growth of early intervention research and service reform around the world.
Professor McGorry has also played a major role in mental health reform in Australia as a key adviser to the Victorian and Federal Governments, and as the Chairman of the Foundation Executive Committee of headspace, 2005-2009. Headspace is a stigma-free “one stop shop” offering holistic multidisciplinary primary mental health care to young people aged 12 – 25. By 2016 headspace centres will be operating in 100 Australian communities, and across 50% of the population. He has successfully led the campaign for the establishment of a complementary national early psychosis programme based on the EPPIC model, and is frequently asked to advise on early psychosis and youth mental health policy internationally.
Professor McGorry has published over 500 papers, numerous book chapters, has edited six books, and has an “h” index of 66 (Web of Science August 2013). He has been the recipient of numerous awards, including the 2013 National Alliance for the Mentally Ill (NAMI) Research Award (USA), the University of Melbourne Dublin Prize in 2012, the Melbourne Award for contribution to community in 2009, the Castilla Del Pino Award in recognition of his significant contribution to the field of Psychiatry in Spanish-speaking countries in 2009, the Australian Government Centenary Medal in 2003 and the Founders’ Medal of the Australian Society for Psychiatric Research in 2001. He was also the 2010 Australian of the Year, and in June of that year received the award of Officer of the Order of Australia (AO) for services to mental health.
Secretary – Paola Dazzan, FRCPsych
Prof Paola Dazzan is Professor of Neurobiology of Psychosis, in the Department of Psychosis Studies at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, and Honorary Consultant Perinatal Psychiatrist, South London and Maudsley NHS Foundation Trust.
She completed her Medical Degree at the University of Cagliari, Italy and obtained a Fellowship in psychiatry that allowed her to pursue her research interests in the UK. She became a Member of the Royal College of Psychiatrists (MRCPsych) in 1998. In 2002, she completed a Master (MSc) in Psychiatry at the Institute of Psychiatry, King’s College London. She trained as a psychiatrist at the Maudsley Hospital, and completed her PhD at the Institute of Psychiatry, King’s College London, in 2006. In 2013 she was nominated Fellow of the Royal College of Psychiatrists (FRCPsych).
Prof Dazzan’s main area of research interest is neuroimaging and its application to the study of early psychosis and postpartum psychoses. She is internationally known for her work on the relationship between magnetic resonance imaging (MRI) data and other biological measures such as neurodevelopmental indices, stress and reproductive hormones. She has studied these phenomena in the early stages of psychosis and her interest has developed to include the progression of brain structural changes over the course of psychoses and the biological substrate of postpartum psychoses. She has a strong interest in understanding how antipsychotic drugs affect brain structure and function, and in exploring how to use imaging to predict response to treatment and clinical outcome. Her work has been extensively published in high impact papers, with more than 200 publications and an h-index of 61 (Google Scholar), and has been recognised by several prestigious International Awards, including the 2014 Academic Researcher of the Year Award from the Royal College of Psychiatrists, and Honorary Membership of the American Psychiatric Association in recognition of her contribution to psychiatry. In 2017 she received the Guy’s, King’s and St Thomas’s Award for “Outstanding Contribution to Student Experience”, for her work as Lead of Psychiatry teaching in the Medical School.
She has a strong interest in addressing gender inequality and promoting diversity in the academic environment, and until recently was the Co-Chair of the Diversity and Inclusion Team of the Institute of Psychiatry, Psychology and Neuroscience, the group that produced the application for the Athena Silver Award obtained by the Faculty. She is a member of the Executive Committees of the Academic and the Perinatal Faculties of the Royal College of Psychiatrists and of the Board of Directors of the Schizophrenia International Research Society. In November 2017 she was appointed Vice Dean International for the Institute of Psychiatry, Psychology and Neuroscience
Robert W. Buchanan, M.D. is a Professor of Psychiatry in the Department of Psychiatry, University of Maryland School of Medicine; Director of the Maryland Psychiatric Research Center (MPRC); and Director of the Maryland Early Intervention Program (EIP). Major research interests include schizophrenia phenomenology; the neuroanatomical and behavioral investigation of the pathophysiology of schizophrenia; and the development of novel pharmacological approaches for negative symptoms, cognitive impairments, treatment-resistant positive symptoms, and the metabolic disturbances and other side effects associated with antipsychotic treatment. Dr. Buchanan has conducted a series of proof of concept and clinical trials examining antipsychotic-reduction strategies in the acute and maintenance treatment of schizophrenia; the use of adjunctive pharmacological agents for the treatment of negative symptoms and cognitive impairments; and the comparative efficacy of clozapine and olanzapine for positive and negative symptoms and cognitive impairment in partially responsive outpatients with schizophrenia. He played a major role in the development and update of the Schizophrenia Patient Outcomes Research Team (PORT) psychopharmacological treatment recommendations. These are a set of evidence-based recommendations that have influenced the development of various sets of treatment algorithms and guidelines for schizophrenia. He is currently funded to evaluate the neural basis of social cognitive impairments and to develop novel therapeutic approaches for the treatment of positive and negative symptoms and cognitive impairments in people with schizophrenia.